BR9914393B1 - método para a preparação de pro-ngf biologicamente ativo, bem como uso de pro-ngf recombinante - Google Patents
método para a preparação de pro-ngf biologicamente ativo, bem como uso de pro-ngf recombinanteInfo
- Publication number
- BR9914393B1 BR9914393B1 BRPI9914393A BR9914393A BR9914393B1 BR 9914393 B1 BR9914393 B1 BR 9914393B1 BR PI9914393 A BRPI9914393 A BR PI9914393A BR 9914393 A BR9914393 A BR 9914393A BR 9914393 B1 BR9914393 B1 BR 9914393B1
- Authority
- BR
- Brazil
- Prior art keywords
- ngf
- biologically active
- beta
- pro
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98119077.0 | 1998-10-09 | ||
| EP98119077A EP0994188B1 (de) | 1998-10-09 | 1998-10-09 | Verfahren zur Gewinnung von aktivem Beta-NGF |
| PCT/EP1999/007613 WO2000022119A1 (de) | 1998-10-09 | 1999-10-11 | VERFAHREN ZUR GEWINNUNG VON AKTIVEM β-NGF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR9914393A BR9914393A (pt) | 2001-06-26 |
| BRPI9914393B1 BRPI9914393B1 (pt) | 2021-06-22 |
| BR9914393B1 true BR9914393B1 (pt) | 2021-06-22 |
Family
ID=8232766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9914393A BR9914393B1 (pt) | 1998-10-09 | 1999-10-11 | método para a preparação de pro-ngf biologicamente ativo, bem como uso de pro-ngf recombinante |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8318671B1 (ko) |
| EP (1) | EP0994188B1 (ko) |
| JP (2) | JP4634611B2 (ko) |
| KR (1) | KR100593831B1 (ko) |
| AT (1) | ATE257514T1 (ko) |
| AU (1) | AU765810B2 (ko) |
| BR (1) | BR9914393B1 (ko) |
| CA (1) | CA2346257C (ko) |
| DE (1) | DE59810555D1 (ko) |
| ES (1) | ES2213861T3 (ko) |
| FR (1) | FR17C0007I2 (ko) |
| NL (1) | NL300894I2 (ko) |
| WO (1) | WO2000022119A1 (ko) |
| ZA (1) | ZA200102780B (ko) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE257514T1 (de) | 1998-10-09 | 2004-01-15 | Scil Proteins Gmbh | Verfahren zur gewinnung von aktivem beta-ngf |
| EP1891966B1 (en) | 2002-12-20 | 2012-02-15 | H. Lundbeck A/S | Modulation of activity of neurotrophins; screening method |
| DK2120997T3 (en) | 2006-12-21 | 2017-05-08 | H Lundbeck As | MODULATION OF PRO-NEUROTROPHIN ACTIVITY |
| RS54220B1 (en) | 2011-12-19 | 2015-12-31 | Wacker Chemie Ag | NEW PRONGF MUTANTS AND THEIR APPLICATIONS IN BETA-NGF PRODUCTION |
| CN103880943A (zh) * | 2014-01-20 | 2014-06-25 | 厦门北大之路生物工程有限公司 | 一种rhNGF成熟肽的制备方法 |
| CN106519024A (zh) * | 2015-09-15 | 2017-03-22 | 三生国健药业（上海）股份有限公司 | 一种用于去除单克隆抗体中异构体的复性液及复性方法 |
| EP3406259A1 (en) | 2017-05-24 | 2018-11-28 | Dompé farmaceutici S.p.A. | Neurotrophins for use in the treatment of hearing loss |
| CN108467428A (zh) * | 2018-03-26 | 2018-08-31 | 江苏中新医药有限公司 | 一种清除rhNGF中N端截短及异常变异体的方法 |
| US20210079053A1 (en) | 2018-04-27 | 2021-03-18 | Chiesi Farmaceutici Spa | Production of nerve growth factor (ngf) and of muteins thereof |
| AU2019343514A1 (en) | 2018-09-17 | 2021-04-15 | Chiesi Farmaceutici S.P.A. | Agent for treatment of dermatological disorders |
| CN110093394B (zh) * | 2019-05-10 | 2023-10-03 | 重庆科润生物医药研发有限公司 | 一种蛋白包涵体及重组人β-神经生长因子的制备方法 |
| JP2022548367A (ja) | 2019-09-17 | 2022-11-18 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 眼科障害の処置または防止における使用のための薬剤 |
| IL302317A (en) | 2020-10-28 | 2023-06-01 | Dompe Farm Spa | Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them |
| EP4039269A1 (en) | 2021-02-05 | 2022-08-10 | Dompe' Farmaceutici S.P.A. | Ngf isoform for use in the treatment of ocular pathologies |
| JP2024514176A (ja) | 2021-04-13 | 2024-03-28 | ドンペ・ファルマチェウティチ・ソシエタ・ペル・アチオニ | Ｎｇｆを用いた神経障害性角膜疼痛の処置 |
| EP4311554A1 (en) | 2022-07-29 | 2024-01-31 | Dompé farmaceutici S.p.a. | Combination for use in ophthalmology |
| EP4316505A1 (en) | 2022-08-05 | 2024-02-07 | Dompé farmaceutici S.p.a. | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
| EP4342485A1 (en) | 2022-09-23 | 2024-03-27 | Dompe' Farmaceutici S.P.A. | Ngf for the treatment of spasticity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169762A (en) * | 1983-03-03 | 1992-12-08 | Genentech, Inc. | Human nerve growth factor by recombinant technology |
| US5453363A (en) | 1985-10-23 | 1995-09-26 | Boehringer Mannheim Gmbh | Process for the activation of t-PA or Ing after genetic expression in prokaryotes |
| US5683894A (en) | 1988-04-29 | 1997-11-04 | University Of California | Recombinant nerve growth factor |
| US5235043A (en) * | 1990-04-06 | 1993-08-10 | Synergen, Inc. | Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins |
| US5606031A (en) | 1990-04-06 | 1997-02-25 | Lile; Jack | Production and purification of biologically active recombinant neurotrophic protein in bacteria |
| DE4139000A1 (de) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf |
| DE4405179A1 (de) | 1994-02-18 | 1995-08-24 | Hoechst Ag | Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken |
| WO1996008562A1 (de) * | 1994-09-12 | 1996-03-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin | Biologisch aktive, von neurotrophinen abgeleitete moleküle |
| US5935824A (en) * | 1996-01-31 | 1999-08-10 | Technologene, Inc. | Protein expression system |
| US6342585B1 (en) | 1996-06-11 | 2002-01-29 | Roche Diagnostics Gmbh | Method of activating denatured protein |
| ATE257514T1 (de) | 1998-10-09 | 2004-01-15 | Scil Proteins Gmbh | Verfahren zur gewinnung von aktivem beta-ngf |
-
1998
- 1998-10-09 AT AT98119077T patent/ATE257514T1/de active
- 1998-10-09 ES ES98119077T patent/ES2213861T3/es not_active Expired - Lifetime
- 1998-10-09 DE DE59810555T patent/DE59810555D1/de not_active Expired - Lifetime
- 1998-10-09 EP EP98119077A patent/EP0994188B1/de not_active Expired - Lifetime
-
1999
- 1999-10-11 CA CA002346257A patent/CA2346257C/en not_active Expired - Lifetime
- 1999-10-11 AU AU10348/00A patent/AU765810B2/en active Active
- 1999-10-11 US US09/807,096 patent/US8318671B1/en not_active Expired - Lifetime
- 1999-10-11 BR BRPI9914393A patent/BR9914393B1/pt not_active IP Right Cessation
- 1999-10-11 KR KR1020017004512A patent/KR100593831B1/ko active IP Right Grant
- 1999-10-11 WO PCT/EP1999/007613 patent/WO2000022119A1/de active IP Right Grant
- 1999-10-11 JP JP2000576009A patent/JP4634611B2/ja not_active Expired - Lifetime
-
2001
- 2001-04-04 ZA ZA200102780A patent/ZA200102780B/en unknown
-
2010
- 2010-04-22 US US12/765,229 patent/US8501439B2/en not_active Expired - Lifetime
- 2010-09-06 JP JP2010199387A patent/JP5275306B2/ja not_active Expired - Lifetime
-
2017
- 2017-09-27 FR FR17C0007C patent/FR17C0007I2/fr active Active
- 2017-09-28 NL NL300894C patent/NL300894I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL300894I2 (nl) | 2018-02-01 |
| CA2346257C (en) | 2005-03-01 |
| EP0994188A1 (de) | 2000-04-19 |
| CA2346257A1 (en) | 2000-04-20 |
| AU765810B2 (en) | 2003-10-02 |
| US20100203589A1 (en) | 2010-08-12 |
| EP0994188B1 (de) | 2004-01-07 |
| US8501439B2 (en) | 2013-08-06 |
| ES2213861T3 (es) | 2004-09-01 |
| FR17C0007I2 (fr) | 2018-11-09 |
| JP2002527062A (ja) | 2002-08-27 |
| ZA200102780B (en) | 2002-07-04 |
| US8318671B1 (en) | 2012-11-27 |
| WO2000022119A1 (de) | 2000-04-20 |
| JP2010280717A (ja) | 2010-12-16 |
| BR9914393A (pt) | 2001-06-26 |
| ATE257514T1 (de) | 2004-01-15 |
| JP4634611B2 (ja) | 2011-02-16 |
| DE59810555D1 (de) | 2004-02-12 |
| JP5275306B2 (ja) | 2013-08-28 |
| FR17C0007I1 (fr) | 2017-11-17 |
| KR20010083900A (ko) | 2001-09-03 |
| AU1034800A (en) | 2000-05-01 |
| KR100593831B1 (ko) | 2006-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9914393B1 (pt) | método para a preparação de pro-ngf biologicamente ativo, bem como uso de pro-ngf recombinante | |
| Jortikka et al. | Immobilisation causes longlasting matrix changes both in the immobilised and contralateral joint cartilage | |
| Poole et al. | Analysis of the morphology and function of primary cilia in connective tissues: a cellular cybernetic probe? | |
| BR0211194A (pt) | Produção de derivados de queratina solúveis | |
| BRPI0410884A (pt) | composição de ração para uso em um animal de estimação, e, método para o controle de peso em um animal de estimação | |
| AR020048A1 (es) | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. | |
| CL2009000648A1 (es) | Propeptido bmp-11 modificado en el residuo 98 de una secuencia bmp-11 humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; metodo para preparar el propeptido, celula recombinante; uso del propeptido para tratar desordenes musculares, neuromusculares, metabolicos, y degenerativos de los huesos (divisional sol.224-02). | |
| BRPI0411552A (pt) | anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea | |
| BR0314038A (pt) | Anticorpo humano isolado, método de tratar uma doença mediada com il-1 em um paciente, composição farmacêutica, cadeias pesada e leve, e, método de mapeamento de epitopo de um antìgeno selecionado | |
| Lei et al. | A new method for xenogeneic bone graft deproteinization: comparative study of radius defects in a rabbit model | |
| WO1996017924A3 (en) | Novel hedgehog-derived polypeptides | |
| AR030631A1 (es) | Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis | |
| BR9913763A (pt) | Partìculas de polivinilareno, processo para a preparação de partìculas de polivinilareno porosas, e, uso das partìculas | |
| BRPI0514074A (pt) | aperfeiçoamentos em composições em bloco para lavatório | |
| NO20050247L (no) | Lavmolekylaert oversulfatert polysakkarid | |
| AR069892A1 (es) | Furina recombinante libre de proteinas sustancialmente animal y metodos para producirla. composicion. | |
| Paolella et al. | Effect of microfragmented adipose tissue on osteoarthritic synovial macrophage factors | |
| ES2119779T3 (es) | Solubilizacion de proteinas en formas activas. | |
| AR045671A1 (es) | Moleculas de union de nogo a y su uso farmaceutico | |
| Zuev et al. | The comparative characteristics of stimulators of reparative osteogenesis in the treatment of periodontal diseases | |
| WO2001014407A3 (de) | Rückfaltung von membranproteinen durch verwendung zweifer unterschieldlichen detergentien | |
| BR0213756A (pt) | Sistema e método para configurar remotamente um rádio, e, estrutura de dados em um perfil de usuário localizado em um banco de dados | |
| NO20023841L (no) | Anvendelse av glukokortikoidreseptorantagonister for forebygging og behandling av sykdommer av reproduksjonssystemet hos menn | |
| WO2004017972A8 (en) | Biologic skin repair and enhancement | |
| BR9811531A (pt) | Preparação de proteìnas mutadas humanas em células humanas por meio de recombinação homóloga |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: WACKER CHEMIE AG (DE) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/10/1999, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 23A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2691 DE 02-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |